INHALED NO FOR THE PREVENTION AND TX OF CHRONIC LUNG DISEASE IN PRETERM INFNT

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。在美国，早产儿慢性肺病（CLD）已成为最常见、最致命、最昂贵的新生儿肺部疾病。据估计，全国的患病率为1万至1.5万例。目前预防和治疗婴儿肺部疾病的治疗方法，包括产前皮质类固醇治疗，表面活性剂替代，以及产后类固醇，维生素A，利尿剂和支气管扩张剂的使用，并没有导致临床显著的CLD降低。患有最严重CLD的婴儿气道阻力增加，其表现与肺动脉高压合并肺心病一致。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic lung disease (CLD) of prematurity has emerged as the most common, lethal and expensive remaining neonatal pulmonary disorder in the United States. The estimated prevalence is 10,000-15,000 cases in the nation. Current therapeutic approaches to prevention and treatment of lung disease of infants, which include antenatal corticosteroid treatment, surfactant replacement, and postnatal administration of steroids, Viatmin A, diuretics and bronchodilators, have not resulted in clinically significant decreases in CLD. Infants with the most severe forms of CLD develop increased airway resistance and findings consistent with pulmonary hypertension with cor pulmonale.